I det samme studie var der efter 5 år ingen stigning i risikoen for apopleksi, herunder hæmoragisk, iskæmisk, embolisk apopleksi, ikke- specificeret apopleksi og transitorisk iskæmisk hændelse hos Fablyn- behandlede patienter.
In the same study at 5 years, there was no increase in the risk of stroke including hemorrhagic, ischemic, embolic stroke, stroke type unspecified and transient ischemic attacks in FABLYN-treated patients.